Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial | #urticaria Pipeline Drugs Market
Gefällt mir
Kommentar
Teilen
Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial | #urticaria Pipeline Drugs Market